Hepatic steatosis and hepatic iron overload modify the association of iron markers with glucose metabolism disorders and metabolic syndrome. (22nd March 2021)

• Record Type: Journal Article
• Authors: Pitchika, Anitha; Kühn, Jens‐Peter; Schipf, Sabine; Nauck, Matthias; Dörr, Marcus; Lerch, Markus M.; Kromrey, Marie‐Luise; Felix, Stephan B.; Markus, Marcello R. P.; Rathmann, Wolfgang; Völzke, Henry; Ittermann, Till
• Is Part Of: Liver international. Volume 41:Number 8(2021)
• Page Start: 1841
• Page End: 1852
• Publication Date: 2021-03-22
• Subjects: ferritin -- impaired glucose metabolism -- interaction -- MRI -- transferrin -- type 2 diabetes; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.14868
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background: Iron status has been linked with impaired glucose metabolism (IGM), type 2 diabetes mellitus (T2DM) and the metabolic syndrome (MetS), but the role of hepatic steatosis or iron overload on these associations remains uncertain. Methods: We analysed data from 2310 participants without known T2DM of the population‐based Study of Health in Pomerania (SHIP‐TREND, Germany) through logistic regression models. We tested additive and multiplicative interactions between ferritin and hepatic steatosis or iron overload. Results: Serum ferritin was positively associated with IGM (OR per 100 µg/L: 1.11 [1.01, 1.23]), T2DM (OR per 100 µg/L: 1.20 [1.06, 1.36]) and MetS (OR per 100 µg/L: 1.11 [1.02, 1.20]) in the total population as well as in participants without hepatic iron overload. However, the synergistic effect of higher ferritin concentrations and hepatic iron overload showed stronger associations with IGM and T2DM. Similarly, while ferritin was positively associated with T2DM and MetS even in the absence of hepatic steatosis, the synergistic effect of higher ferritin concentrations and hepatic steatosis showed stronger associations with IGM, T2DM and MetS. Transferrin was associated with isolated impaired glucose tolerance but not with T2DM and MetS. Conclusions: Our study suggests that ferritin may be associated with glucose metabolism disorders and MetS even in people without hepatic steatosis or iron overload. However, in individuals with higher ferritin concentrations, the presence of hepatic steatosis may indicate stronger risk for glucose metabolism disorders and MetS, while the presence of hepatic iron overload may indicate stronger risk only for glucose metabolism disorders.